Beranda › Kanker Kandung Kemih › North Carolina › Durham
Uji klinis Kanker Kandung Kemih di Durham, NC
20 studi untuk Kanker Kandung Kemih mencari peserta di lokasi sekitar Durham (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Durham VA Medical Center, Durham
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Menerima pesertaFase 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Menerima pesertaFase 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Menerima pesertaFase 1/2
- Duke University Medical Center (location of scans), Durham
- Duke University Medical Center - Duke University Hospital (location of scans), Durham
- Duke University Medical Center, Durham
- dan 1 lainnya
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Menerima pesertaFase 1
- Biorepository and Precision Pathology Center (BRPC), Durham
- Duke Cancer Institute, Durham
- Substrate Services Core Research Support (SSCRS), Durham
DESTINY-PANTUMOUR04
Menerima pesertaStudi observasional
- Research Site, Durham
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Menerima pesertaFase 1
- Duke University Medical Center - Duke Cancer Center, Durham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Menerima pesertaStudi observasional
- UNC- Chapel Hill, Chapel Hill · 10 mi jauhnya
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Menerima pesertaFase 2
- University of North Carolina, Chapel Hill · 10 mi jauhnya
The Vanguard Study: Testing a New Way to Screen for Cancer
Menerima pesertaSukarelawan sehat diterima
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Menerima pesertaFase 1
- University of North Carolina (UNC) - Chapel Hill, Chapel Hill · 10 mi jauhnya
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Menerima pesertaFase 2/3
- Research Site, Chapel Hill · 10 mi jauhnya
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Menerima pesertaFase 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Menerima pesertaFase 1/2
- Duke Health - Duke Cancer Center, Durham
- UNC Chapel Hill Hospital, Chapel Hill · 10 mi jauhnya
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
Menerima pesertaStudi observasional
- University of North Carolina, Chapel Hill · 10 mi jauhnya
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Menerima pesertaFase 2
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauhnya
- UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill · 10 mi jauhnya
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Menerima peserta
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · 10 mi jauhnya
Characterizing the Microvascular Environment of Bladder Cancer With Super-Resolution Ultrasound Localization Microscopy
Menerima pesertaStudi observasional
- Duke University, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Menerima pesertaFase 1
- Duke Cancer Institute, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi jauhnya
Uji klinis Kanker Kandung Kemih di kota lain
- New York City, NY35 studi
- Nashville, TN31 studi
- Houston, TX31 studi
- Dallas, TX27 studi
- Boston, MA26 studi
- Washington, DC26 studi
- Los Angeles, CA24 studi
- Baltimore, MD24 studi
- St. Louis, MO22 studi
- Philadelphia, PA21 studi
- Seattle, WA21 studi
- Edison, NJ21 studi
Studi lain di Durham
- Kanker Payudara63 studi
- Kanker (semua jenis)58 studi
- Kanker Paru Non-Sel Kecil39 studi
- Mieloma Multipel37 studi
- Kanker Metastatik33 studi
- Leukemia Mieloid Akut33 studi
- Kanker Paru32 studi
- Kanker Prostat32 studi
- Kanker Kolorektal28 studi
- Leukemia Limfositik Kronis27 studi
- Kanker Ovarium27 studi
- Gagal Jantung26 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.